| |
Learn how Transmission Electron Microscopy (TEM) enables precise quantification of virus-like particles (VLPs) in unprocessed bulk material. Discover the importance of TEM in viral safety testing and cell line characterization. Check out our scientific poster! .png)
|
|
Today’s Big NewsOct 22, 2024 |
|
Wednesday, October 29, 2024 | 11am ET / 8am PT Real-world data is essential to gaining insights into a patient’s diagnostic journey. However, many pharma companies may not be using lab data to its full potential. Join us to discuss how today’s robust lab data sources can help improve patient access and time to treatment, leading to better patient outcomes. Register now. 
|
|
| By Angus Liu Activist investor Starboard Value is baring its teeth at Pfizer management, more openly going after CEO Albert Bourla’s job in a new presentation. |
|
|
|
By Nick Paul Taylor Roche has returned the rights to UCB’s anti-tau antibody bepranemab, walking away from a $120 million bet on the Alzheimer’s disease drug candidate on the cusp of the release of phase 2a data. |
By Conor Hale Tarver had held the interim position since late July, when Jeff Shuren announced his retirement after 15 years in the post. |
By Fraiser Kansteiner Telix on Tuesday unveiled the spin-off of Rhine Pharma—a new entity born from a collaboration between Telix and Germany’s Heidelberg University Hospital—which is setting out on a mission to expand access to radiopharmaceuticals for cancer treatment and imaging. |
By Nick Paul Taylor Sangamo Therapeutics has identified a shortcut to market for its Fabry disease candidate, aligning with the FDA on a pathway that could slash three years from the time to market and free it from the need to run an additional registrational study. Shares in Sangamo jumped 33% to $1.22 in the wake of the news. |
By Andrea Park A group of U.S. senators are digging into the direct-to-consumer telehealth platforms launched by Eli Lilly and Pfizer this year, in search of any indication that the services could create conflicts of interest for prescribers. |
By Conor Hale Peytant Solutions’ AMStent system has a metal frame encased in a processed material made of amnion, the pliable membrane that helps form the amniotic sac. It holds open the airways of patients who may have trouble breathing due to growing tumors. |
By Nick Paul Taylor AstraZeneca has rolled out a fresh TV spot for its blockbuster-to-be Breztri, hitting the message that the product frees chronic obstructive pulmonary disease patients to leave their bad days behind and cruise into a brighter future. |
By Kevin Dunleavy In federal bankruptcy court in Houston, Texas, the U.S. Trustee—the Department of Justice’s unit that oversees bankruptcy cases—has filed a motion to dismiss a Johnson & Johnson subsidiary's Chapter 11 bid to settle more than 60,000 talc lawsuits. |
By Andrea Park The upcoming winter months bring with them the annual cold and flu season, as well as “cuffing season” for singles everywhere, and consumer health giant Reckitt is capitalizing on both occurrences. |
By James Waldron Editas Medicine is pushing its in vivo gene therapy strategy to the top of its agenda, boasting proof-of-concept data and signing a $238 million biobucks pact at the same time as it searches for a partner for its more advanced ex vivo sickle cell disease (SCD) medicine. |
By Conor Hale Geneious Luma aims to focus on monoclonal and multispecific antibodies. It’s the first part of what Dotmatics describes as a multimodal suite for biopharma researchers. |
By James Waldron AvenCell Therapeutics has secured $112 million in series B funds as the Novo Holdings-backed biotech seeks clinical proof that it can generate CAR-T cells that can be turned “on” once inside a patient. |
By Ben Adams Leo Pharma is launching a new U.S. healthcare awareness campaign aimed at doctors to boost their understanding of a specific type of eczema. |
Fierce podcasts Don’t miss an episode |
| In this week’s episode of “The Top Line,” we catch up with three past Fierce 15 honorees to gain their insights, experiences and visions for the evolving biotech landscape. |
|
|---|
|
|
|
Thursday, November 14, 2024 | 11am ET / 8am PT Join us for a deep dive into the development and manufacturing of monoclonal antibodies. We’ll explore an industry case study, providing access to key findings, top strategies and solutions for enhancing productivity and efficiency in mAb production. Don’t miss out on important insights, register now. 
|
|
Whitepaper Discover how independent adjudication can safeguard your clinical trials from misidentified adverse events and enhance the credibility of your results. Sponsored by: WCG |
Whitepaper Learn how to evaluate quality documentation to help you select the right raw materials at early decision points for your cell-based manufacturing processes. Presented by: Thermo Fisher Scientific |
eBook Need the superpowers to select the right lab equipment? Sponsored by: PHC Corporation of North America |
Whitepaper Take a brief journey through some of the efforts that Lonza has made to optimize the manufacturability of bsAbs and other formats, and take a glance towards future directions with an emphasis on the upstream aspects. Sponsored by: Lonza |
Whitepaper How can an emerging company attract the right partner for a therapeutic asset (& optimize its value in a transaction)? This paper offers some insights. Presented by: Blue Matter |
Whitepaper Unlock the Future of Biotherapeutics with Catalent Biologics! Sponsored by: Catalent Biologics |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| The Lighthouse at Pier 61 in New York City |
|
|
| |
|
